FrancophonIA/DGT-Translation_Memory huggingface dataset:
English: EFSA-Q-2008-478
Lithuanian: EFSA–Q–2008–478
English: EFSA-Q-2008-479
Lithuanian: EFSA–Q–2008–479
English: EFSA-Q-2008-480
Lithuanian: EFSA–Q–2008–480
English: EFSA-Q-2008-328
Lithuanian: EFSA–Q–2008–328
English: EFSA-Q-2008-121
Lithuanian: EFSA–Q–2008–121
English: EFSA-Q-2008-317
Lithuanian: EFSA–Q–2008–317
English: EFSA-Q-2008-318
Lithuanian: EFSA–Q–2008–318
English: EFSA-Q-2008-319
Lithuanian: EFSA–Q–2008–319
English: EFSA-Q-2008-320
Lithuanian: EFSA–Q–2008–320
English: EFSA-Q-2008-119
Lithuanian: EFSA–Q–2008–119
English: EFSA-Q-2008-329
Lithuanian: EFSA–Q–2008–329
English: EFSA-Q-2008-330
Lithuanian: EFSA–Q–2008–330
English: Following an application from Potters Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Mumomega® on central nervous system development (Question No EFSA-Q-2008-328) [9]. The claim proposed by the applicant was worded as follows: ‘Mumomega® provides the nourishments that support healthy central nervous system development’.
Maltese: Wara applikazzjoni minn Potters Ltd., imressqa skont l-Artikolu 14(1)(b) tar-Regolament (KE) Nru 1924/2006, l-Awtorità ntalbet tagħti opinjoni dwar indikazzjoni dwar is-saħħa relatata mal-effetti tal-Mumomega® dwar l-iżvilupp tas-sistema nervuża ċentrali (Mistoqsija Nru EFSA-Q-2008-328) [9] L-indikazzjoni proposta mill-applikant kienet tgħid dan li ġej: “Mumomega® jipprovdi n-nutrijenti li jsostnu żvilupp b’saħħtu tas-sistema nervuża ċentrali”.
English: Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on coordination (Question No EFSA-Q-2008-121) [10]. The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain coordination’.
Maltese: Wara applikazzjoni minn Efamol Ltd., imressqa skont l-Artikolu 14(1)(b) tar-Regolament (KE) Nru 1924/2006, l-Awtorità ntalbet tagħti opinjoni dwar indikazzjoni dwar is-saħħa relatata mal-effetti tal-Efalex® dwar il-koordinament (Mistoqsija Nru EFSA-Q-2008-121) [10] L-indikazzjoni proposta mill-applikant kienet tgħid dan li ġej: “L-Efalex® jista’ jgħin fiż-żamma tal-koordinazzjoni”.
English: Following an application from Potters Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Eye q baby® on the central nervous system development (Question No EFSA-Q-2008-119) [15]. The claim proposed by the applicant was worded as follows: ‘Eye q baby® provides the nourishments that support healthy central nervous system development’.
Maltese: Wara applikazzjoni minn Potters Ltd., imressqa skont l-Artikolu 14(1)(b) tar-Regolament (KE) Nru 1924/2006, l-Awtorità ntalbet tagħti opinjoni dwar indikazzjoni dwar is-saħħa relatata mal-effetti tal-Eye q® dwar l-iżvilupp tas-sistema nervuża ċentrali (Mistoqsija Nru EFSA-Q-2008-119) [15] L-indikazzjoni proposta mill-applikant kienet tgħid dan li ġej: “Eye q® jipprovdi n-nutrijenti li jsostnu żvilupp b’saħħtu tas-sistema nervuża ċentrali”.
English: Eye q baby®
Maltese: Eye q®
English: Eye q®
Slovak: Eye q baby®